How COVID-19 Testing Demand Threw off Thermo Fisher’s Acquisition of Qiagen
Health Advances
SEPTEMBER 18, 2020
The mystery lies in whether this deal will ever be resurrected and at what price. CEO Thierry Bernard noted “very significant demand for products used in COVID-19 testing.” Investors took notice and hedge fund manager Davidson Kempner publicly urged Qiagen to seek a higher price—reportedly pushing for $13.4B—based
Let's personalize your content